PMC:7228307 / 2437-2655 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T13","span":{"begin":10,"end":18},"obj":"Body_part"}],"attributes":[{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"next‐gen\" antibody therapeutics.\n\nIntroduction\nThe regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immune therapy. Since then, mAbs have become one of"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T17","span":{"begin":34,"end":46},"obj":"Sentence"},{"id":"T18","span":{"begin":47,"end":182},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"next‐gen\" antibody therapeutics.\n\nIntroduction\nThe regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immune therapy. Since then, mAbs have become one of"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T13","span":{"begin":10,"end":18},"obj":"Body_part"}],"attributes":[{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"next‐gen\" antibody therapeutics.\n\nIntroduction\nThe regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immune therapy. Since then, mAbs have become one of"}

{"project":"LitCovid-sentences","denotations":[{"id":"T17","span":{"begin":34,"end":46},"obj":"Sentence"},{"id":"T18","span":{"begin":47,"end":182},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"next‐gen\" antibody therapeutics.\n\nIntroduction\nThe regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immune therapy. Since then, mAbs have become one of"}